pubmed.ncbi.nlm.nih.gov

Clinical Trials of Stem Cell Therapy for Cerebral Ischemic Stroke - PubMed

  • ️Wed Jan 01 2020

Review

Clinical Trials of Stem Cell Therapy for Cerebral Ischemic Stroke

Masahito Kawabori et al. Int J Mol Sci. 2020.

Abstract

Despite recent developments in innovative treatment strategies, stroke remains one of the leading causes of death and disability worldwide. Stem cell therapy is currently attracting much attention due to its potential for exerting significant therapeutic effects on stroke patients. Various types of cells, including bone marrow mononuclear cells, bone marrow/adipose-derived stem/stromal cells, umbilical cord blood cells, neural stem cells, and olfactory ensheathing cells have enhanced neurological outcomes in animal stroke models. These stem cells have also been tested via clinical trials involving stroke patients. In this article, the authors review potential molecular mechanisms underlying neural recovery associated with stem cell treatment, as well as recent advances in stem cell therapy, with particular reference to clinical trials and future prospects for such therapy in treating stroke.

Keywords: clinical trials; ischemic stroke; regenerative medicine; stem cell; transplantation.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1

Unsolved issues regarding stem cell treatment for ischemic stroke. The most effective and safest method of stem cell therapy has not been established. The challenges include the choice of cell, cell dose, transplantation routes, and patient type. ES cell: embryonic stem cell, iPS: induced pluripotent stem cell.

Figure 2
Figure 2

The relationship between cell types, dose, and patient characteristics in clinical trials. Note that intravenous transplantation is preferred in the acute phase, while intracerebral transplantation is preferred in the chronic phase. MNC: CD34: CD34 positive hematopoietic stem cells derived from mononuclear cells, MSC: Mesenchymal stem/stromal cell, NSC: Neural stem/progenitor cell, OEC: Olfactory ensheathing cell. The number represents the approximate amount of cells transplanted per patient (cells/body).

Similar articles

Cited by

References

    1. Goyal M., Menon B.K., van Zwam W.H., Dippel D.W., Mitchell P.J., Demchuk A.M., Davalos A., Majoie C.B., van der Lugt A., de Miquel M.A., et al. Endovascular thrombectomy after large-vessel ischaemic stroke: A meta-analysis of individual patient data from five randomised trials. Lancet. 2016;387:1723–1731. doi: 10.1016/S0140-6736(16)00163-X. - DOI - PubMed
    1. Barbosa da Fonseca L.M., Gutfilen B., Rosado de Castro P.H., Battistella V., Goldenberg R.C., Kasai-Brunswick T., Chagas C.L., Wajnberg E., Maiolino A., Salles Xavier S., et al. Migration and homing of bone-marrow mononuclear cells in chronic ischemic stroke after intra-arterial injection. Exp. Neurol. 2010;221:122–128. doi: 10.1016/j.expneurol.2009.10.010. - DOI - PubMed
    1. Battistella V., de Freitas G.R., da Fonseca L.M., Mercante D., Gutfilen B., Goldenberg R.C., Dias J.V., Kasai-Brunswick T.H., Wajnberg E., Rosado-de-Castro P.H., et al. Safety of autologous bone marrow mononuclear cell transplantation in patients with nonacute ischemic stroke. Regen. Med. 2011;6:45–52. doi: 10.2217/rme.10.97. - DOI - PubMed
    1. Bhasin A., Kumaran S.S., Bhatia R., Mohanty S., Srivastava M.V.P. Safety and Feasibility of Autologous Mesenchymal Stem Cell Transplantation in Chronic Stroke in Indian patients. A four-year follow up. J. Stem Cells Regen. Med. 2017;13:14–19. - PMC - PubMed
    1. Bhasin A., Srivastava M., Bhatia R., Mohanty S., Kumaran S., Bose S. Autologous intravenous mononuclear stem cell therapy in chronic ischemic stroke. J. Stem Cells Regen. Med. 2012;8:181–189. - PMC - PubMed

Publication types

MeSH terms